United States - English - NLM (National Library of Medicine)

msn laboratories private limited - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - maintenance of normal sinus rhythm (delay in af/afl recurrence) dofetilide capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because dofetilide capsules can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). conversion of atrial fibrillation/flutter dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. dofetilide capsules have not been shown to be effective in patients with paroxysmal atrial fibrillation. dofetilide is contraind

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

msn laboratories private limited , india - nebivolol hydrochloride - tablets - 10mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

msn laboratories private limited , india - nebivolol hydrochloride - tablets - 2.5mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

msn laboratories private limited , india - nebivolol hydrochloride - tablets - 5mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

msn laboratories private limited , india - dapoxetine hydrochloride - tablets - 60

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

msn laboratories private limited , india - dapoxetine hydrochloride - tablets - 30 mg

United States - English - NLM (National Library of Medicine)

msn laboratories private limited - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride capsules usp 250 mg is indicated in the treatment of patients with wilson's disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride capsules usp 250 mg is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. trientine hydrochloride capsules usp 250 mg and penicillamine cannot be considered interchangeable. trientine hydrochloride capsules usp 250 mg should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. unlike penicillamine, trientine hydrochloride capsules usp 250 mg is not recommended in cystinuria or rheumatoid arthritis. the absence ofa sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride capsules usp 250 mg was reported not to be effective i

United States - English - NLM (National Library of Medicine)

msn laboratories private limited - pregabalin (unii: 55jg375s6m) (pregabalin - unii:55jg375s6m) - pregabalin extended-release tablets are indicated for the management of: -  neuropathic pain associated with diabetic peripheral neuropathy - postherpetic neuralgia efficacy of pregabalin extended-release tablets has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures. pregabalin extended-release tablets is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [ see warnings and precautions (5.1, 5.2),adverse reactions (6)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to pregabalin during pregnancy. to provide information regarding the effects of in utero exposure to pregabalin extended-release tablets, physicians are advised to recommend that pregnant patients taking pregabalin extended-release tablets enroll in the nort

United States - English - NLM (National Library of Medicine)

msn laboratories private limited - lacosamide (unii: 563ks2pqy5) (lacosamide - unii:563ks2pqy5) - lacosamide tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older. additional pediatric use information is approved for ucb, inc.'s vimpat ® (lacosamide) tablets. however, due to ucb, inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as lacosamide, during pregnancy. encourage women who are taking lacosamide during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. risk summary there are no adequate data on the developmental risks associated with the use of lacosamide in pregnant women. lacosamide produced developmental toxicity (increased embryofetal and perinatal mortality, growth deficit) in rats following administration during pregnancy. d

United States - English - NLM (National Library of Medicine)

msn laboratories private limited - pregabalin (unii: 55jg375s6m) (pregabalin - unii:55jg375s6m) - pregabalin capsule is indicated for: - management of neuropathic pain associated with diabetic peripheral neuropathy - management of postherpetic neuralgia - adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older -  management of fibromyalgia - management of neuropathic pain associated with spinal cord injury pediatric use information is approved for pfizer's lyrica (pregabalin) capsules and oral  solution products. however, due to pfizer's marketing exclusivity rights, this drug product  is not labeled with that pediatric information. pregabalin is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see warnings and precautions (5.2)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to pregabalin during pregnancy. to provide information regarding the